DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of ...

LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

A new survey from Dexcom suggests that living with Type 2 diabetes can have significant impacts not only on physical health but on mental health, too. The diabetes devicemaker conducted the survey ...

Mar. 19, 2025 4:00 AM ETDexCom, Inc. (DXCM) “With policymakers increasingly focused on digital transformation in healthcare, now is the time to push for greater investment in CGM technology as a core ...

New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful ...